Moderna, Inc. $MRNA Stock Acquired by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 44.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,692 shares of the company’s stock after buying an additional 7,267 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Moderna were worth $4,562,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Aire Advisors LLC purchased a new position in shares of Moderna in the third quarter valued at approximately $233,000. Crescent Grove Advisors LLC acquired a new position in shares of Moderna in the third quarter valued at approximately $243,000. Halter Ferguson Financial Inc. acquired a new position in shares of Moderna in the third quarter valued at approximately $369,000. Axxcess Wealth Management LLC purchased a new stake in Moderna during the 3rd quarter worth approximately $214,000. Finally, Quadrant Capital Group LLC purchased a new stake in Moderna during the 3rd quarter worth approximately $466,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on MRNA. Berenberg Bank increased their target price on shares of Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a report on Friday, September 11th. Citigroup downgraded shares of Moderna from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, September 30th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Moderna in a research report on Friday, September 25th. Rothschild & Co Redburn lowered Moderna from a “neutral” rating to a “sell” rating and upped their price objective for the stock from $40.00 to $81.00 in a research report on Thursday, September 3rd. Finally, Bank of America increased their price objective on Moderna from $170.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, October 9th. Seven analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and four have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $103.95.

Moderna Stock Down 17.6%

Shares of Moderna stock opened at $202.63 on Friday. Moderna, Inc. has a one year low of $22.28 and a one year high of $254.48. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The business has a 50-day simple moving average of $170.05 and a 200-day simple moving average of $96.24.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million for the quarter, compared to analysts’ expectations of $102.93 million. During the same quarter last year, the company earned ($2.13) earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts forecast that Moderna, Inc. will post -6.11 earnings per share for the current year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Detailed Phase 3 INTerpath-001 results showed positive recurrence-free survival and distant metastasis-free survival for intismeran autogene, Moderna’s individualized mRNA cancer vaccine used with Merck’s Keytruda. The results support the program’s potential to become a major non-COVID growth driver. Merck and Moderna INTerpath-001 Results
• Positive Sentiment: Moderna advanced its mRNA bird-flu vaccine into a late-stage trial, expanding its pipeline into pandemic influenza. The company also said it plans to reserve 20% of related manufacturing capacity for low- and middle-income countries if the vaccine is approved. Moderna Starts Late-Stage Bird Flu Trial
• Neutral Sentiment: Moderna’s addition to the Nasdaq-100 has increased institutional visibility and contributed to recent momentum, but the sharp run-up also left the stock vulnerable to profit-taking when new clinical information emerged. Moderna Nasdaq-100 Inclusion
• Negative Sentiment: Partial melanoma-vaccine data circulated online before Moderna’s scheduled ESMO presentation. Although the findings appeared clinically meaningful, investors viewed the leak as an information-quality and timing problem, while the lack of a fresh surprise raised “sell-the-news” concerns. Trading was temporarily halted because of volatility. Reuters Moderna Cancer Vaccine Data Report
• Negative Sentiment: TD Cowen raised its price target to $90 but maintained a Hold rating, leaving substantial downside relative to the stock’s recent trading level and reinforcing valuation concerns. TD Cowen Moderna Price Target
• Negative Sentiment: A law firm announced an investigation into potential securities-law violations related to Moderna’s October 22 disclosure. The announcement does not establish wrongdoing, but it adds headline and legal risk following the abrupt decline. Moderna Securities Investigation

Insiders Place Their Bets

In other news, President Stephen Hoge sold 40,294 shares of Moderna stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the completion of the sale, the president directly owned 1,525,858 shares of the company’s stock, valued at approximately $219,921,913.54. The trade was a 2.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James M. Mock sold 34,836 shares of the business’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock worth $33,875,904 in the last 90 days. Corporate insiders own 10.80% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.